Mahaveer Khemka, MD
Cardiology · Anaheim, CANPI 1568449965
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 263 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,133 and has fallen 72.7% since, to $309 in 2025.
Across 263 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$895
- AstraZeneca$734
- Novartis$623
- Gilead$370
- E.r. Squibb & Sons, L.L.C.$370
- Merck$351
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,91597%
- Education$1603%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 43 | $895 |
| AstraZeneca | 27 | $734 |
| Novartis | 51 | $623 |
| Gilead | 44 | $370 |
| E.r. Squibb & Sons, L.L.C. | 17 | $370 |
| Merck | 10 | $351 |
| Boehringer Ingelheim | 9 | $292 |
| Astellas Pharma US Inc | 4 | $192 |
| Bayer | 8 | $191 |
| Shionogi Inc | 6 | $126 |
| Pfizer | 7 | $122 |
| Esperion Therapeutics, Inc. | 5 | $115 |
| Amgen | 5 | $100 |
| Viiv Healthcare Company | 4 | $92 |
| Lilly USA, LLC | 4 | $65 |
| Boston Scientific | 2 | $62 |
| Scpharmaceuticals Inc. | 2 | $53 |
| Preventice Services, LLC | 1 | $51 |
| Theratechnologies Inc. | 3 | $44 |
| Irhythm Technologies, Inc. | 2 | $44 |
| AbbVie(2 entities) | 2 | $42 |
| Shield Therapeutics Inc | 1 | $25 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Abbott | 1 | $22 |
| Bristol Myers Squibb | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| EMD Serono, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,075 in reported general payments places this provider in the 80th percentile of 156 cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 188 | $205,771 |
| EliquisApixaban | 168 | $180,210 |
| FarxigaDapagliflozin Propanediol | 92 | $81,858 |
| JardianceEmpagliflozin | 30 | $37,729 |
| TrulicityDulaglutide | 25 | $31,575 |
| JanuviaSitagliptin Phosphate | 24 | $26,922 |
| XareltoRivaroxaban | 20 | $25,860 |
| OzempicSemaglutide | 12 | $12,229 |
| KerendiaFinerenone | 14 | $9,417 |
| Metoprolol Succinate | 255 | $3,259 |
| Rosuvastatin Calcium | 202 | $3,239 |
| Nifedipine ErNifedipine | 106 | $2,728 |
| Amiodarone Hcl | 53 | $2,727 |
| Bisoprolol Fumarate | 117 | $2,371 |
| ClopidogrelClopidogrel Bisulfate | 199 | $2,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $623 | $205,771188 claims |
| PfizerEliquis | $122 | $180,210168 claims |
| AstraZenecaFarxiga | $734 | $81,85892 claims |
| Boehringer IngelheimJardiance | $292 | $37,72930 claims |
| Lilly USA, LLCTrulicity | $65 | $31,57525 claims |
| MerckJanuvia | $351 | $26,92224 claims |
| Johnson & JohnsonXarelto | $895 | $25,86020 claims |
| BayerKerendia | $191 | $9,41714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 156 cardiology providers in California.
Other cardiology in Anaheim
- Norman LeporBeverly Hills$1.9M
- Sanjay KaulLos Angeles$1.1M
- Ramtin AgahMountain View$361K
- Jamshid MaddahiLos Angeles$59K
- Bipin JoshiFresno$51K
- Anil ShahSanta Ana$49K
- Thomas KimSanta Ana$47K
- Hooman MadyoonLos Angeles$24K
- Lakhjit SandhuFresno$19K
- Prabhtej BraraSanta Monica$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.